ITRM Stock Analysis: Buy, Sell, or Hold?
ITRM - Iterum Therapeutics plc Ordinary Share
$0.31
-0.01 (-2.80%)
▼
5d:
-5.22%
30d:
-13.79%
90d:
-53.19%
HOLD
LOW Confidence
Analysis Updated: Feb 3, 2026 12:00 AM ET
Earnings: Feb 06, 2026
1d
Get Alerted When ITRM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
9 traders called ITRM this week
80% bullish • 3 bearish
80% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ITRM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ITRM shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ITRM is currently trading at $0.31, which is considered oversold relative to its 30-day fair value range of $0.31 to $0.35.
Technical Outlook: Technically, ITRM is in a strong downtrend. The price is currently testing key support at $0.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+1651.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ITRM is in a strong downtrend. The price is currently testing key support at $0.30. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.50 (+1651.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.31 -
$0.35
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 1651.6% below Wall St target ($5.50)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Fair Price Analysis
30-Day Fair Range
$0.31 -
$0.35
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.30
Resistance Level
$0.39
Current Trend
Strong Downtrend
Technical data as of
Feb 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.01
Wall Street Target
$5.50
(+1651.6%)
Revenue Growth (YoY)
-100.0%
Last updated: February 04, 2026 11:07 AM ET
Data refreshes hourly during market hours. Next update: 12:07 PM
Data refreshes hourly during market hours. Next update: 12:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ITRM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 67 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 65 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
